Posts
- Category: Patent Litigation (continued)
- FTC Challenges Drug Acquisitions
- Attempt to Monopolize Resin Industry Case Goes Forward
- Qualcomm Patent Standard Challenge Dismissed on Standing Grounds
- Patented/Generic Drug Manufacturers Settle Patent/Antitrust Suit
- Printer Ink Cartridge Patent Suit Spurs Antitrust Counterclaim
- DuPont Files Antitrust Counter-claim Against Monsanto
- Patent Reverse Payments Involving Cipro
- EC Issues Report on Drug Patenting Issues
- Enforcement Agencies Continue to Challenge Patent Infringement Reverse Payments
- Ocean Spray Hit With Antitrust Claims in Patent Suit
- Court Permits Patent Acquisition Antitrust Case to Proceed
- Drug Wholesalers Sue Merck for Delaying Generic Singulair
- Court Upholds Jury Verdict Finding Petition in Opposition to Generic Drugs Baseless
- Failure to Disclose Patent to Standard Setting Organization Can Be Monopolization
- Federal Circuit to Revisit Sony/Philips Recordable CD Agreement Claim
- Second Circuit Permits Generic Drug Price Fixing Case to Move Forward
- US Supreme Court Denies Cert in FTC v. Rambus
- Abbott Settles Tricor Action Filed by States
- EC Investigating Lundbeck Regarding Generic Drug Entry
- EC Examining Reverse Payment Settlements
- Georgia Federal Court Upholds Reverse Payment Drug Patent Settlement
- Second Circuit Urges En Banc Review While Upholding Reverse Payment Drug Settlement
- Drug Retailers Allege Conspiracy to Block Generic Provigil
- Drug Patent Reverse Payment Settlement Challenge Thrown Out
- Drug Purchasers' Challenge to Exclusion of Generic Dismissed
- Generic Toprol-XL Litigation Goes Forward
- Casino Game Antitrust Suit to Proceed to Trial
- Philips Antitrust Counterclaims Against Masimo Postponed Until After Patent Infringement Trial
- Mylan Antitrust Claim Against AstraZeneca Tossed
- EU General Court Upholds Fine for Blocking Generic Drug Market Entry
- Patent Challenge Dismissed Because Brand Market Too Narrow
- Fraud on Patent Office Claim to Move Forward
- NCAA Standard for Lacrosse Stickhead Design Not Anticompetitive
- Exclusive of Generic Drugs Monopolization Case Goes Forward
- Standard Setting Abuse Case to Move Forward
- Attack on MPEG Patent Pool Dismissed
- Patent Exclusion Suit Dismissed on Standing Grounds
- EU Requests Patent Settlement Information Between Pharmaceutical Companies and Generic Drug Manufacturers
- Plavix Purchasers’ Class Action Dismissed
- SanDisk's Walker Process Claim Moves Forward
- Key Cutting Machine Monopolization Case to Move Forward
- Drug Patent Sham Litigation Case Dismissed
- En Banc Federal Circuit Narrows Patent Misuse Defense
- Refusal to Sell Drug Needed to Obtain Approval for Generic Version to Move Forward
- Sham Patent Infringement Claim Against Ocean Spray to Move Forward
- FTC Reports 60% Increase in Pay-for-Delay Generic Drug Deals
- Monoplization Case Against Pfizer to Go Forward
- Asparagus Seed Patent Challenge Needs to Allege Knowing Fraud to Support Antitrust Claims
- Class Certified in Case Alleging that It Delayed Generic Entrant
- Organic Farmers Seek to Invalidate Monsanto’s Genetically-Modified Seed Patents
- Motions to Dismiss Denied in Prosthetics Gel Liner Patent Case
- Pay-for-Delay Generic Drug Deals Decline in Europe While Numbers Rise in US
- Generics vs. Prilosec Lawsuit Dismissed by SDNY
- DOJ Antitrust Concerns Alter Novell Patent Deal
- Court Lifts Motorola’s Infringement Injunction Against Apple’s iPad and iPhone Sales in Germany
- DOJ and EC Approve Google Acquisition of Motorola, Other Technology Patent Transactions
- Microsoft Challenges Motorola/Google’s Patent Practices in EC Competition Complaint
- EC Competition Regulator Investigates Samsung Patent Licensing, Litigation
- Pfizer Faces Suit by Health Plans Regarding Its Efforts to Delay Generic Lipitor
- Essential Patents Cannot Block Smartphones from European Markets
- Class Certification Denied In Pineapple Sham Patent Suit
- EU Investigates Motorola’s Smartphone Patent Conduct for Antitrust Violations
- Antitrust Challenge to Flash Memory Maker Dismissed with Leave to Amend
- FTC Pay-for-Delay Drug Patent Challenge Fails
- Antitrust Claim Based on Nike/Apple Joint Venture Dismissed
- FTC Calls for Ban on Injunctions to Enforce Standard-Essential Patents
- Second Circuit Affirms that Blackberry’s Backing out of Joint Production Deal Not Anticompetitive
- Third Circuit and EU: Pay-for-Delay Generic Drug Settlement Can Violate Antitrust Law
- Breach of SSO Commitment Enforceable By Competitors, but Not as Antitrust Violation
- FTC Proposes Closer Scrutiny of Drug Patent Licensing
- Hospital Lacks Standing To Seek Damages in a Challenge to a Tying Arrangment Because It Purchased the Bundle Indirectly
- AndroGel Drug Patent Litigation Not a Sham
- FTC Closes Investigation Into Several Drug Patent Deals
- Federal Circuit to Decide Whether Patent Fraud Antitrust Claims Can Be Asserted Independently of Infringement Claims and Amended Complaint Upheld in Related Flash Memory Monopolization Challenge
- Court Refuses to Dismiss Antitrust Suit Over Mobile Tracking Technology
- Drug Industry Opposes FTC Proposal to Expand the Reportability of Patent Licensing Deals
- DOJ Closes Investigation of Monsanto’s Domestic Seed Business
- Federal Circuit Rules That Direct Purchasers May Sue to Void Patent Obtained by Fraud
- US Supreme Court to Decide Whether Reverse Payment Settlements Between Patented and Generic Drug Manufacturers Violate the Antitrust Laws
- EU High Court Upholds Fine Against Drug Company Improperly Blocking Generic Competition
- Drug Patent Settlements May Include Provisions in Which the Patent Holder Agrees Not to Introduce Its Own Generic Version of the Drug
- Respirator Manufacturer Violates Antitrust Laws by Enforcing Patents Obtained by Fraud
- DOJ Concerned About The Exploitation of Standard-essential Technology Patents Through Unfair Licensing Strategies
- FTC & Google Enter Consent Decree on Patent Issues
- DOJ & USPTO Seek to Prevent Ban on Patented Products
- GSK Settles Generic Flonase Law Suits
- Foreign Drug Maker Lacks Antitrust Standing If It Does Not Compete in the U.S.
- Refusal to Deal on Patent Licensing Case Dismissed
- AAI Supports Notice of Patent Transfers
- EU Finds that Drug Makers Violated Antitrust Laws by Slowing Generic Entry
- Refusal to License USB Patents Case to Move Forward
- Patent Holder Seeks to Litigate Licensing Terms in State Court Under Recent Supreme Court Case
- EU Finds Google Too Aggressive in Attempt to Enforce Patents
- Federal Court Remands Reverse Payment Case to State Court
- Pay-for-Delay Challenge to Move Forward
- Bayer Settles Cipro Pay-For-Delay Suit for $74 Million
- US Supreme Court Permits Antitrust Challenges to Reverse Payment Settlements
- EU Fines Patented Drug Maker and Generics for Reverse Payment Settlement
- ITC Sees No Consumer Harm in Banning Imports of Electronic Products
- FTC Considering Investigating Patent Trolls
Plugin by dagondesign.com